CCCC - CIK 0001662579
C4 Therapeutics, Inc. (CCCC) reported net income of -$104.99M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$104.99M | +0.3% |
| FY 2024 | -$105.32M | +20.5% |
| FY 2023 | -$132.49M | -3.4% |
| FY 2022 | -$128.18M | -52.8% |
| FY 2021 | -$83.89M | -26.5% |
| FY 2020 | -$66.33M | -94.5% |
| FY 2019 | -$34.10M | - |
C4 Therapeutics, Inc. (CCCC) reported net income of -$104.99M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, C4 Therapeutics, Inc.'s net income declined from -$34.10M to -$104.99M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.